Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial -

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Gastrointestinal disorders
Summary
Exploratory RCT (n=82) found pazopanib + best supportive care (BSC) marginally improves progression-free survival vs. BSC alone in this population (median: 3.4 vs. 2.3 months; HR 0.59; 95% CI, 0.37–0.96, p=0.03) with a toxicity profile similar to that reported for other sarcomas.
UKMi comment
A commentary notes that because of the low proportion of patients achieving a response and limited efficacy, despite the cost, it is important to ascertain pazopanib’s mechanism of action and molecular markers to identify patients who will benefit from the drug.
Related links: Comment